Androgen deprivation therapy (ADT) historically represented the milestone for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Recently, combining androgen receptor targeted agents (ARTA) or docetaxel with ADT significantly improved clinical outcomes in this setting. The efficacy of the combined use of an ARTA with docetaxel and ADT (triplet), however, was unknown, and often conflicting data derived from subgroup analysis of randomized phase III trials …
B A Maiorano, U De Giorgi, G Roviello, C Messina, A Altavilla, C Cattrini, A Mennitto, E Maiello, M Di Maio 
ESMO Open, 2022 Sep. 21
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.
